Lymphomatoid granulomatosis risk factors: Difference between revisions
Jump to navigation
Jump to search
Kamal Akbar (talk | contribs) No edit summary |
Kamal Akbar (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
==Risk Factors== | ==Risk Factors== | ||
The most potent risk factor in the development of [[Lymphomatoid granulomatosis]] is EBV infection. Other risk factors include Drug induced immunodeficiency, Immunodeficient diseases, and HIV infection, and organ transplantation.<ref name="pmid25003566">{{cite journal| author=Neparidze N, Lacy J| title=Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. | journal=Clin Adv Hematol Oncol | year= 2014 | volume= 12 | issue= 6 | pages= 358-71 | pmid=25003566 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25003566 }} </ref><ref name="pmid29518976">{{cite journal| author=Dojcinov SD, Fend F, Quintanilla-Martinez L| title=EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. | journal=Pathogens | year= 2018 | volume= 7 | issue= 1 | pages= | pmid=29518976 | doi=10.3390/pathogens7010028 | pmc=5874754 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29518976 }} </ref> | *The most potent risk factor in the development of [[Lymphomatoid granulomatosis]] is EBV infection. Other risk factors include Drug induced immunodeficiency, Immunodeficient diseases, and HIV infection, and organ transplantation.<ref name="pmid25003566">{{cite journal| author=Neparidze N, Lacy J| title=Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. | journal=Clin Adv Hematol Oncol | year= 2014 | volume= 12 | issue= 6 | pages= 358-71 | pmid=25003566 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25003566 }} </ref><ref name="pmid29518976">{{cite journal| author=Dojcinov SD, Fend F, Quintanilla-Martinez L| title=EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. | journal=Pathogens | year= 2018 | volume= 7 | issue= 1 | pages= | pmid=29518976 | doi=10.3390/pathogens7010028 | pmc=5874754 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29518976 }} </ref> | ||
===Common Risk Factors=== | ===Common Risk Factors=== | ||
Latest revision as of 17:30, 19 December 2018
|
Lymphomatoid granulomatosis Microchapters |
|
Differentiating Lymphomatoid granulomatosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphomatoid granulomatosis risk factors On the Web |
|
American Roentgen Ray Society Images of Lymphomatoid granulomatosis risk factors |
|
Directions to Hospitals Treating Lymphomatoid granulomatosis |
|
Risk calculators and risk factors for Lymphomatoid granulomatosis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kamal Akbar, M.D.[2]
Overview
The risk factor this disease is commonly EBV infection . One my also develop it in a immunodeficient state, organ transplantation , and HIV infection.
Risk Factors
- The most potent risk factor in the development of Lymphomatoid granulomatosis is EBV infection. Other risk factors include Drug induced immunodeficiency, Immunodeficient diseases, and HIV infection, and organ transplantation.[1][2]
Common Risk Factors
- Common risk factors in the development of Lymphamatoid granulomatosis include:
References
- ↑ Neparidze N, Lacy J (2014). "Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments". Clin Adv Hematol Oncol. 12 (6): 358–71. PMID 25003566.
- ↑ Dojcinov SD, Fend F, Quintanilla-Martinez L (2018). "EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts". Pathogens. 7 (1). doi:10.3390/pathogens7010028. PMC 5874754. PMID 29518976.
- ↑ Song JY, Pittaluga S, Dunleavy K, Grant N, White T, Jiang L, Davies-Hill T, Raffeld M, Wilson WH, Jaffe ES (February 2015). "Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations". Am. J. Surg. Pathol. 39 (2): 141–56. doi:10.1097/PAS.0000000000000328. PMC 4293220. PMID 25321327.
- ↑ Costiniuk, Cecilia T.; Karamchandani, Jason; Bessissow, Ali; Routy, Jean-Pierre; Szabo, Jason; Frenette, Charles (2018). "Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report". BMC Infectious Diseases. 18 (1). doi:10.1186/s12879-018-3128-3. ISSN 1471-2334.
- ↑ Barakat, Athar; Grover, Karan; Peshin, Rohit (2014). "Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis". SpringerPlus. 3 (1): 751. doi:10.1186/2193-1801-3-751. ISSN 2193-1801.
- ↑ Shah, Sujal; Smith, Megan; Butler, Randall (2018). "A Case of Hodgkin Lymphoma Mimicking Lymphomatoid Granulomatosis Diagnosed at Autopsy". Laboratory Medicine. 49 (1): 80–86. doi:10.1093/labmed/lmx065. ISSN 0007-5027.